article thumbnail

FDA Expands Indication for Impella Heart Pumps for Pediatric Patients

DAIC

with SmartAssist and Impella CP with SmartAssist heart pumps, granting premarket approval (PMA) for use in specific pediatric patients with symptomatic acute decompensated heart failure (ADHF) and cardiogenic shock. and Impella CP, both left-sided heart pumps, for pediatric patients with symptomatic ADHF and cardiogenic shock.

article thumbnail

Magenta Medical, Developer of World’s Smallest Heart Pump, Closes $105M Financing Round

DAIC

Magenta's technology stands at the forefront of innovation in the MCS field and has the potential to significantly improve outcomes in patients with severe cardiovascular conditions,” said Eric Snyder, Partner, Venture Investments, Novo Holdings US. The financing will be used to advance the company’s U.S. Magenta completed a U.S.

article thumbnail

A more-Comers populAtion trEated with an ultrathin struts polimer-free Sirolimus stent: an Italian post-maRketing study (the CAESAR registry)

Frontiers in Cardiovascular Medicine

First-generation polymer-free stent technologies, such as sirolimus- and probucol-eluting stents (PF-SES), have shown an excellent safety and efficacy profile. Patients with left main (LM) disease, cardiogenic shock (CS), or severely reduced left-ventricular ejection fraction (LVEF) were excluded.

Stents 64
article thumbnail

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

ET Main Tent (Hall B1) Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients with Small Aortic Annuli: Primary Outcomes from the Randomized Smart Trial Effect of Edetate Disodium Based Chelation Infusions on Cardiovascular Events in Post-MI Patients with Diabetes: The TACT2 Trial Long-term Beta-blocker Treatment (..)

article thumbnail

How Virtual-First Cardiology is Reshaping the Patient Experience

The Beat Blog

However, thanks to the rapid pace of technological growth, many of those obstacles to accessing virtual treatment are rapidly disappearing. As physicians, we know the value of placing a hand on someone’s calf, detecting a subtle drop in body temperature, and knowing that they have decompensated into a low output cardiogenic shock.

article thumbnail

American College of Cardiology (ACC24) Show Preview: Advancing Cardiovascular Care for All

DAIC

SHASTA-2—looks at a new medicine plozasiran on the treatment of hypertriglyceridemia SMART Trial—a head-to-head trial of the self-expanding vs. a balloon-expanding TAVR DanGer Shock—brings equipoise to how cardiogenic shock is treated in general, looking at the use of a transvalvular mico-axial flow pump in patients who have infarct or heart attack (..)

article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)